Results 21 to 30 of about 27,289 (199)

Efficacy and Safety of Spironolactone in the Treatment of Resistant Hypertension：a Meta-analysis [PDF]

Zhongguo quanke yixue, 2022
BackgroundAs a special type of hypertension, resistant hypertension has complex etiology, is difficult to treat, and more likely to lead to target organ damage.
ZHANG Ping, ZOU Jing, GAO Cunzhou, WU Aiping, LI Rongshan
doaj   +1 more source

Pharmacologic inhibition by spironolactone attenuates experimental abdominal aortic aneurysms

Frontiers in Cardiovascular Medicine, 2023
BackgroundAbdominal aortic aneurysms (AAA) are characterized by vascular inflammation and remodeling that can lead to aortic rupture resulting in significant mortality. Pannexin-1 channels on endothelial cells (ECs) can modulate ATP secretion to regulate
Zachary Ladd, Gang Su, Joseph Hartman, Guanyi Lu, Sara Hensley, Gilbert R. Upchurch, Ashish K. Sharma   +6 more
doaj   +1 more source

Spironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO/PKG pathway in the bile-duct-ligated rat. [PDF]

PLoS ONE, 2012
OBJECTIVE: Aldosterone, one of the main peptides in renin angiotensin aldosterone system (RAAS), has been suggested to mediate liver fibrosis and portal hypertension.
Wei Luo, Ying Meng, Hong-Li Ji, Chun-Qiu Pan, Shan Huang, Chang-Hui Yu, Li-Ming Xiao, Kai Cui, Shu-Yuan Ni, Zhen-Shu Zhang, Xu Li   +10 more
doaj   +1 more source

Efficacy of Spironolactone Compared with Doxycycline in Moderate Acne in Adult Females: Results of the Multicentre, Controlled, Randomized, Double-blind Prospective and Parallel Female Acne Spironolactone vs doxyCycline Efficacy (FASCE) Study

Acta Dermato-Venereologica
Acne in adult females is triggered mainly by hormones. Doxycycline is a reference treatment in acne. Spironolactone targets the androgen receptor of sebaceous glands and is prescribed off-label for female adult acne.
Brigitte Dréno, Jean-Michel Nguyen, Ewa Hainaut, Laurent Machet, Marie-Thérèse Leccia, Nathalie Beneton, Jean-Paul Claudel, Philippe Célérier, Marie Le Moigne, Sarah Le Naour, Florence Vrignaud, Alexandra Poinas, Cécile Dert, Aurélie Boisrobert, Laurent Flet, Simon Korner, Amir Khammari   +16 more
doaj   +1 more source

Anti-inflammatory Effect of Spironolactone on Human Peripheral Blood Mononuclear Cells

Journal of Pharmacological Sciences, 2006
.: We evaluated the effect of alacepril, CV-11974, and spironolactone on the production of monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-alpha (TNF-α) in cultured human peripheral blood mononuclear cells stimulated with angiotensin
Miura Ryuzea, Nakamura Kazufumi, Miura Daiji, Miura Aya, Hisamatsu Kenichi, Kajiya Masahito, Nagase Satoshi, Morita Hiroshi, Kusano Kengo Fukushima, Ohe Tohru, Ishihara Kazuhiko   +10 more
doaj   +1 more source

Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial

Contemporary Clinical Trials Communications, 2020
Background: Preclinical studies recently showed that the mineralocorticoid antagonist spironolactone acts also as an antagonist of the NRG1-ERBB4 signaling pathway and improves schizophrenia-like behaviour in Nrg1 transgenic mouse model.
Alkomiet Hasan, Astrid Roeh, Stefan Leucht, Berthold Langguth, Maximilian Hansbauer, Tatiana Oviedo-Salcedo, Sophie K. Kirchner, Irina Papazova, Lisa Löhrs, Elias Wagner, Isabel Maurus, Wolfgang Strube, Moritz J. Rossner, Michael C. Wehr, Ingrid Bauer, Stephan Heres, Claudia Leucht, Peter M. Kreuzer, Stephanie Zimmermann, Thomas Schneider-Axmann, Thomas Görlitz, Susanne Karch, Silvia Egert-Schwender, Beate Schossow, Philipp Rothe, Peter Falkai   +25 more
doaj   +1 more source

Efficacy and safety of iodized lecithin tablets versus spironolactone in alleviating central serous retinopathy among Chinese patients with uncontrolled diabetes

Pakistan Journal of Pharmaceutical Sciences, 2023
To compare the effectiveness and safety of spironolactone versus lecithin-bound iodine in patients with central serous retinopathy (CSR). Chinese diabetes patients aged>18 years with CSR with persistent increased level of subretinal fluid (SRF) were ...
Huihui Gu, Lijun Pu, Suqin Yu
doaj   +1 more source

Do consumers and healthcare professionals report the same adverse event differently? A paired analysis of duplicate vaccine safety reports in Norway

British Journal of Clinical Pharmacology, EarlyView.
Aim This study aimed to compare how Norwegian healthcare professionals (HCPs) and consumers reported the same adverse event (AE) following immunization with vaccines against COVID‐19 during the COVID‐19 pandemic. Specifically, we aimed to compare the extent to which HCPs and consumers reported information relevant for assessing the causal relationship ...
Tommy Emil Dzus, Johaina Sarrage, Hilde Samdal, François Montastruc, Elena Rocca   +4 more
wiley   +1 more source

Spironolactone in Alcohol Use Disorder (SAUD): Introduction to an ongoing double-blind, placebo-controlled, ascending dose, Phase 1b study

European Psychiatry
Introduction Efforts are critically needed to increase the armamentarium of options that clinicians can use to treat patients with alcohol use disorder (AUD).
A. Leko, M. Farokhnia, S. T. Weiss, C. A. Blake, L. A. Farinelli, L. Leggio   +5 more
doaj   +1 more source

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Balcinrenone (previously AZD9977) is a novel selective non‐steroidal mineralocorticoid receptor antagonist (MRA) with a differential mechanism of action relative to approved MRAs. The aim of this trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone in participants with mild and moderate hepatic impairment ...
Anna L. Eriksson, Deeyen Karsanji, Bonifride Tuyishimire, Joanna Parkinson, Maria Heijer, Tadeusz Pawlik, Judith Hartleib‐Geschwindner, Maria Leonsson‐Zachrisson, Hans Ericsson   +8 more
wiley   +1 more source